Abstract Library

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#2999 Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours

Introduction: Increased levels of serotonin secretion are associated with mesenteric fibrosis (MF) in small intestinal neuroendocrine tumors (SI-NETs). However, only a proportion of patients with increased serotonin production will develop mesenteric fibrosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Blazevic A

Authors: Blazevic A, Iyer A, Van Velthuysen M, Hofland J, Franssen G,

Keywords: Small-intestinal neuroendocrine tumors, mesenteric fibrosis, serotonin, tryptophan metabolism, proteomics,

#2909 Serotonin-Secreting NeuroEndocrine Neoplasms of the Pancreas: Which Are the Primary Pancreatic Carcinoids?

Introduction: Serotonin-secreting pancreatic neuroendocrine neoplasms (5-HT-secreting pNENs) are very rare. They are characterised by high urinary 5-hydroxyindole-acetic acid (5-HIAA) levels (or high serum 5-HT levels).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Milanetto A, Fassan M, Gais Zürcher A, David A, Pasquali C,

Keywords: Pancreatic neuroendocrine neoplasm, primary pancreatic carcinoid, serotonin-secreting pancreatic tumour, serotonin-producing pancreatic tumour,

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy

Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hota S, Cananea E, Martin W, Clement D, Solis B,

Keywords: Neuroendocrine tumours, carcinoid syndrome, telotristat ethyl,